SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Donald Trump's highly anticipated State of the Union address is driving significant speculative interest and intense political debate around DJT, with the community focused on his economic claims, character, and the broader political divide, anticipating increased volatility for the stock.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

Recent record-breaking battery swap milestones are fueling intense discussion around NIO, with bulls touting the unique Battery-as-a-Service model as a game-changer for profitability and a potential short squeeze, while bears continue to dismiss it as a 'cash burn' and 'bull trap' amid ongoing price volatility.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN CRYPTO is trending as its community actively fosters a resilient culture, rallying for long-term growth leading up to the upcoming "4/20" period. Participants emphasize the project's foundational strength, often noting its perceived outperformance of traditional cannabis stocks and aligning it with the broader cultural and scientific potential of the plant.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending strongly as the market anticipates its upcoming earnings, with community sentiment driven by recent strategic acquisitions in the AI/HPC data center space and bullish remarks from a political figure about data centers needing their own power. High short interest further fuels speculation of a potential squeeze as the company solidifies its position as a key digital infrastructure provider.

Santacruz Silver Mining Ltd. engages in the acquisition, exploration, and development of mineral properties. It operates through the following segments: Bolivar, Porco, Caballo Blanco Group, San Lucas Group, Zimapan, and Corporate and Other. The Bolivar segment focuses on mine and processing plants. The Porco segment is invovled in mine and processing plants. The Caballo Blanco Group segment includes the Tres Amigos, Colquechaquita mines and the Don Diego processing plant. The San Lucas Group segment refers to Reserva mine and San Lucas feed sourcing business. The Zimapan segment consists of mine and processing plant. The company was founded on January 24, 2011 and is headquartered in Vancouver, Canada.

Santacruz Silver Mining Ltd

Santacruz Silver Mining Ltd.

Santacruz Silver Mining Ltd. (SCZMF), now listed on Nasdaq, is trending as investors enthusiastically discuss its significant undervaluation, robust silver production, and strong financial position, anticipating substantial growth as it gains broader institutional attention amid rising silver prices.

Hut 8 Corp. operates as a Bitcoin miner that focuses on mining. It provides digital asset mining, hosting, and managed infrastructure operation services. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 is trending due to its significant pivot into AI infrastructure, highlighted by a substantial 15-year data center deal with a major hyperscaler, positioning it as a leader in the high-performance computing space. This strategic shift and recent analyst upgrades are fueling community excitement, with many investors viewing its relative strength positively amidst broader crypto market volatility, though some express concerns about its valuation.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros Discovery is trending as its board acknowledged Paramount Skydance's revised $31 per share cash offer, which includes a ticking fee and enhanced termination fees, could be a superior proposal to Netflix's current bid. The community is actively discussing the financial certainty and regulatory risks associated with both offers, reflecting the ongoing intensity of this acquisition battle.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending after delivering an impressive beat-and-raise earnings report, notably achieving positive GAAP net income for the first time, and raising its 2026 guidance. The community is actively discussing its AI disruptor edge and proprietary data as key drivers, despite ongoing skepticism around broader software sector sentiment.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing a significant short squeeze, driven by escalating investor confidence in its Anktiva cancer treatment following recent international approvals and compelling presentations by its CEO. The community is intensely focused on the potential for further upside as short sellers face mounting pressure, emphasizing the drug's groundbreaking science and market disruption over any speculative political catalysts.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. (BNAI) is rallying significantly amid discussions of a potential short squeeze, with a low float and its AI-focused business drawing comparisons to other high-flying AI stocks. Community chatter highlights renewed RegSHO listing and substantial institutional interest as key drivers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether VYNE...

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE...

Penny Stocks To Watch Now - December 17th

Direxion Daily TSLA Bear 1X Shares, Canopy Growth, VYNE Therapeutics, Better Choice, Rezolve AI, Bitfarms, and iRobot are the seven Penny stocks to watch today, according to MarketBeat's stock...

VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of VYNE Therapeutics Inc. (NASDAQ: VYNE) and Yarrow Bioscience, Inc. is fair to VYNE shareholders. Upon completion...

VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates

VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +10.53% and +12.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +43.48% and -31.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates

Metagenomi (MGX) delivered earnings and revenue surprises of +20.59% and +20.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of +22.22% and -9.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of +17.24% and +5.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

BTIG and H.C. Wainwright downgraded Vyne Therapeutics following topline results from the company’s Phase 2b trial of repibresib gel in nonsegmental vitiligo, which failed to meet both primary and secondary endpoints.BTIG analyst Julien Harrison downgraded the stock to ‘Neutral’ from ‘Buy’ and said the company will analyze the full dataset to guide next steps. He also noted that Vyne intends to seek a development and commercialization partner for repibresib.&nbsp;Harrison added that an update is expected in the coming weeks on both repibresib and VYN202, which is currently under partial clinical hold by the U.S. Food and Drug Administration.H.C. Wainwright analyst Joseph Pantginis also downgraded the stock to ‘Neutral’ from ‘Buy’ and removed the firm’s $4.5 price target, calling the trial outcome “a surprise” that “puts the company in a precarious position.”&nbsp;He said the firm will remain on the sidelines pending further clarity on repibresib, additional VYN202 data, or potential new asset acquisitions.Vyne said that the Phase 2b trial was a randomized, double-blind, vehicle-controlled study conducted at 45 sites across North America, enrolling 177 participants. The trial evaluated the once-daily topical administration of repibresib gel at 1%, 2%, and 3% concentrations compared to vehicle.&nbsp;The primary endpoint, defined as the proportion of patients achieving at least a 50% improvement in the Facial Vitiligo Area Scoring Index (F-VASI50) at week 24, was not met. The trial also missed a key secondary endpoint (F-VASI75).However, the company stated that the highest dose group showed a nominally statistically significant treatment effect in percent change from baseline (CFB) in both F-VASI and T-VASI scores at week 24.&nbsp;Vyne stated that the outcome was likely affected by a high vehicle effect and a higher-than-expected dropout rate in the active arms. As a result, the company has discontinued treatment in the extension phase and will terminate the trial.The company&nbsp;reported approximately $39.6 million in cash, cash equivalents, and investments as of June 30.&nbsp;Treatment-emergent adverse events (TEAEs) were more frequent in the repibresib arms, with application site pain being the most common. Eight subjects in the treatment group discontinued due to AEs, compared to none in the vehicle group. Most TEAEs were mild and resolved during the study.CEO David Domzalski said the company was disappointed by the outcome but remains confident in the potential of its InhiBET BET inhibitor platform.On Stocktwits, retail sentiment for Vyne was ‘extremely bullish’ late Wednesday amid&nbsp;an 11,800% surge in 24-hour message volume.One user said they went long on Vyne at&nbsp;$0.4189, calling the selloff part of the biotech cycle. “Every setback is a setup for a comeback,” they wrote, adding that while the vitiligo trial missed, the underlying science still showed promise.&nbsp;They also pointed to the FDA's recent move&nbsp;regarding the company’s psoriasis program and noted that Vyne has sufficient cash to operate into late 2026.<stembedurl>https://stocktwits.com/BulldogTheDip/message/623071473</stembedurl>Another user highlighted Vyne’s $39 million cash position, suggesting the stock could attract activist investors like Tang Capital Management. “If they step in, we could see a bounce,” the user wrote.<stembedurl>https://stocktwits.com/MadHatterTrades74/message/623051900</stembedurl><a href="https://stocktwits.com/symbol/VYNE">Vyne’s stock</a> has declined 88.1% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Pharma stock. (Photo credit: Getty Images)

Vyne Hit With Downgrades After Repibresib Misses Endpoints In Vitiligo Trial; Traders Still Eye Rebound

The company plans to seek a development and commercialization partner for repibresib and expects to provide an update on both repibresib and VYN202, which are currently under partial FDA clinical hold, in the coming weeks. 

Equity

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercializes solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded in October 2011 and is headquartered in Bridgewater, NJ.

VYNE Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

Current Price	$0.5752
Prev Close	$0.5964
Open	$0.60
Dividend Yield	0.00%
50-Day Moving Average	$0.5549
Beta	1.02
Avg. Volume	503,565.00
PE Ratio	-0.76

52-Week High	$2.83
52-Week Low	$0.2805
Market Capitalization	$19.85M
EPS (Annual)	-$0.9353
Price to Book	0.59
Revenue Per Employee	$38,538.46

VYNE
VYNE Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest VYNE News

VYNEVYNE Therapeutics Inc